Published in Asian J Androl on July 04, 2014
Erectile dysfunction. Nat Rev Dis Prim (2016) 0.76
Implanted Muscle-Derived Stem Cells Ameliorate Erectile Dysfunction in a Rat Model of Type 2 Diabetes, but Their Repair Capacity Is Impaired by Their Prior Exposure to the Diabetic Milieu. J Sex Med (2016) 0.76
Depressive symptoms and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: the Dogo Study. Int J Impot Res (2016) 0.75
Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases. Res Rep Urol (2016) 0.75
Identification and Functional Verification of MicroRNAs in the Obese Rat With Erectile Dysfunction. Sex Med (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (2004) 39.54
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res (1999) 7.14
Waist circumference as a measure for indicating need for weight management. BMJ (1995) 7.01
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA (2004) 5.95
The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med (2011) 3.68
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45
Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism (2001) 3.25
Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis (2008) 2.56
A prospective study of risk factors for erectile dysfunction. J Urol (2006) 2.25
Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care (2005) 2.15
A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc (2009) 1.98
Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol (2006) 1.82
Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol (2005) 1.74
A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol (2013) 1.70
Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol (2011) 1.66
Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology (2000) 1.65
Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation (2004) 1.47
Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obes Res (1997) 1.43
Central obesity is an independent predictor of erectile dysfunction in older men. J Urol (2006) 1.31
Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl (2010) 1.30
Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med (2009) 1.28
Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes (2013) 1.25
Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc (2001) 1.23
Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab (2011) 1.14
Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med (2009) 1.13
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol (2013) 1.10
Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. Int J Androl (2009) 1.09
Hypogonadism and metabolic syndrome. J Endocrinol Invest (2011) 1.07
Overweight and obesity prevalence and determinants in Italy: an update to 2010. Eur J Nutr (2012) 1.07
Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl (2009) 1.04
The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl (2009) 1.01
Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev (2012) 1.00
Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med (2008) 0.99
Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol (2000) 0.98
Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. Eur J Endocrinol (2011) 0.98
Sexual function and obesity. Int J Obes (Lond) (2007) 0.97
Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J (2009) 0.96
Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl (2011) 0.96
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med (2011) 0.96
The hormonal control of ejaculation. Nat Rev Urol (2012) 0.96
Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med (2009) 0.96
Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med (2013) 0.94
Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med (2010) 0.93
Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res (2006) 0.93
Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med (2010) 0.93
Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med (2009) 0.92
Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med (2009) 0.92
Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl (2006) 0.90
Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. J Sex Med (2009) 0.89
Psycho-biological correlates of free-floating anxiety symptoms in male patients with sexual dysfunctions. J Androl (2006) 0.88
Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study sexual function questionnaire. J Sex Med (2008) 0.88
How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl (2012) 0.87
A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med (2007) 0.87
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol (2012) 0.87
Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male (2008) 0.87
Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl (2011) 0.86
Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl (2009) 0.86
Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology (2002) 0.86
Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res (2003) 0.86
Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med (2008) 0.86
Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med (2010) 0.86
Update in testosterone therapy for men. J Sex Med (2011) 0.86
Is obesity a further cardiovascular risk factor in patients with erectile dysfunction? J Sex Med (2010) 0.85
Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med (2010) 0.85
Obesity and sexual dysfunction in younger Danish men. J Sex Med (2008) 0.85
Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med (2011) 0.84
SIEDY scale 3, a new instrument to detect psychological component in subjects with erectile dysfunction. J Sex Med (2012) 0.84
Neurophysiology/pharmacology of erection. Int J Impot Res (2001) 0.82
Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med (2013) 0.82
Poor response to alprostadil ICI test is associated with arteriogenic erectile dysfunction and higher risk of major adverse cardiovascular events. J Sex Med (2011) 0.82
Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med (2013) 0.81
Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med (2009) 0.81
Pulse pressure independently predicts major cardiovascular events in younger but not in older subjects with erectile dysfunction. J Sex Med (2010) 0.81
The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction. J Sex Med (2013) 0.81
FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol (2013) 0.81
Nicotine potentiates the nitrergic relaxation responses of rabbit corpus cavernosum tissue via nicotinic acetylcholine receptors. Eur J Pharmacol (2006) 0.78
Duplex ultrasound evaluation of cavernosal peak systolic velocity and waveform acceleration in the penile flaccid state: clinical significance in the assessment of the arterial supply in patients with erectile dysfunction. Int J Androl (2000) 0.78
Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. Int J Impot Res (2002) 0.78
"It takes two to tango": the relational domain in a cohort of subjects with erectile dysfunction (ED). J Sex Med (2012) 0.78
Uses and misuses of the new pharmacotherapy of obesity. Ann Med (1999) 0.76
In response. Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med (2013) 0.76
Duplex Doppler sonography of the flaccid penis: potential role in the evaluation of impotence. J Clin Ultrasound (2000) 0.75
Perceived reduced sleep-related erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med (2011) 0.75
Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc (2009) 2.28
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int (2014) 1.73
Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol (2004) 1.72
Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol (2006) 1.70
A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol (2013) 1.70
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate (2013) 1.67
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol (2011) 1.60
Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med (2013) 1.59
DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther (2011) 1.59
Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care (2011) 1.58
Frailty and sexual health in older European men. J Gerontol A Biol Sci Med Sci (2012) 1.58
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med (2010) 1.54
The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab (2011) 1.53
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin (2011) 1.48
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev (2006) 1.47
The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med (2010) 1.46
Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry (2013) 1.45
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf (2014) 1.44
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism (2008) 1.43
Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates. J Androl (2010) 1.41
Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index? Fertil Steril (2013) 1.41
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med (2009) 1.32
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol (2009) 1.30
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2008) 1.30
Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med (2011) 1.28
Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med (2009) 1.27
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol (2009) 1.25
Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology (2004) 1.25
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2007) 1.23
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med (2009) 1.22
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol (2011) 1.16
Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology (2006) 1.15
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care (2008) 1.14
Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab (2011) 1.14
Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol (2012) 1.13
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res (2011) 1.12
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care (2007) 1.12
Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke (2007) 1.12
Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev (2006) 1.11
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol (2013) 1.10
Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med (2014) 1.10
Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2003) 1.08
Diagnostic crossover and outcome predictors in eating disorders according to DSM-IV and DSM-V proposed criteria: a 6-year follow-up study. Psychosom Med (2011) 1.08
Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate (2012) 1.07
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res (2012) 1.06
Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med (2006) 1.05
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev (2011) 1.05
Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health (2013) 1.01
The metabolic syndrome in treatment-seeking obese persons. Metabolism (2004) 1.00
Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med (2012) 1.00
Clinical correlates of erectile dysfunction and premature ejaculation in men with couple infertility. J Sex Med (2012) 1.00
Cystatin C reference values and aging. Clin Biochem (2006) 0.99
Correlations between binge eating and emotional eating in a sample of overweight subjects. Appetite (2009) 0.99
Finger sepsis in two poorly controlled diabetic patients with reuse of lancets. Diabetes Care (2002) 0.99
Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med (2009) 0.99
Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med (2008) 0.99
Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med (2007) 0.98
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol (2012) 0.98
The association between varicocele, premature ejaculation and prostatitis symptoms: possible mechanisms. J Sex Med (2009) 0.98
Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med (2009) 0.97
Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med (2009) 0.97
Testosterone and cardiovascular risk. Intern Emerg Med (2013) 0.97
Serum PSA as a predictor of testosterone deficiency. J Sex Med (2013) 0.96
The hormonal control of ejaculation. Nat Rev Urol (2012) 0.96
Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clin Exp Res (2007) 0.96
Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res (2002) 0.96
Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med (2006) 0.95